Advances in PSMA-based immunotherapy in metastatic castration-resistant prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) has a very bad prognosis with most patients dying within two years of diagnosis [1]. Available therapies for mCRPC are often associated with poor tissue selectivity, and side effects including high systemic toxicity and drug resistance. Great progress has been made with the help of PSMA (prostate-specific membrane antigen), a glycoprotein highly expressed on the cell membrane of malignant prostate tumor cells, which constitutes an attractive therapeutic candidate for both diagnosis and treatment of mCRPC [2]. Briefly, ­PSMA-based immunotherapy specifically targets tissues expressing the protein, either the primary tumor or metastases. However, PSMA is expressed in normal tissues such as salivary glands, kidney, ovary, breast, the neo-vasculature of non-prostatic tumors and intestine, too, and high uptakes of radiopharmaceuticals might lead to dose-limiting toxicities [2-4].

ProstACT GLOBAL: a phase 3 study with 177Lu-DOTA-rosopatamab

TLX591 consists of the humanized monoclonal antibody rosopatamab (HuJ591), targeting an epitope of the extracellular domain of PSMA, conjugated to DOTA, a chelating agent (DOTA-­HuJ591). This chelator conjugated antibody can be linked to different radioisotopes for diagnostic (89Zirconium) or therapeutic purposes (177Lutetium, 111Indium or 90Yttrium) [5, 6]. Rosopatamab has a high affinity for PSMA, its target epitope, and does not bind to complement [6]. So far, 177Lu-HuJ591 has been tested in more than 100 patients in four phase 1 and 2 studies with single as well as repeated and fractionated doses [5]. Rosapatamab has further been evaluated in combination with standard-of-care docetaxel in a phase 1 study including 15 patients with progressive mCRPC and showed preliminary encouraging efficacy [7]. During EANM 2023, Neel Patel presented the design of the ongoing ProstACT GLOBAL multinational, multicenter, randomized, controlled, open-label phase 3 study (NCT04876651) [8]. The efficacy and safety of 177Lu-­DOTA-rosopatamab plus best standard of care (SoC), as compared to best SoC alone, is investigated in patients with progressive mCRPC despite previous treatment with a novel androgen-axis drug (NAAD). Patients considered eligible must present with a PSMA-positive disease and at least one metastatic site, as assessed by 68Gallium-PSMA-11 positron emission tomography/computerized tomography (68Ga-PSMA-11 PET/CT) scan, have received prior therapy with either enzalutamide or abiraterone plus prednisone, as well as prior taxane therapy unless they have refused it or are ineligible; patients must also present adequate hematological function as demonstrated by normal platelet count (≥ 150 x 109/L) and normal hemoglobin (≥ 10 g/dL).

The planned 387 patients will be randomized 2:1 to either two 14-days-apart single intravenous injections of 76 milli­curies (mCi) each of 177Lu-DOTA-­rosopatamab (equivalent to a 45 mCi/m2 dose in a standard 1.7 m2 individual) on top of best SoC, or best SoC alone. Stratification factors will be based on prior taxane therapy, prior NAAD setting (non-metastatic versus castration-sensitive), disease burden as defined by bone metastases number with a cut-off at 10, and visceral disease (or not).

The primary objective of ProstACT GLOBAL is the radiographic progression-free survival (rPFS); secondary endpoints further evaluate the 5-year overall survival (OS), the tumor objective response rate (ORR) and the time to symptomatic skeletal event (TTSSE), as well as the assessment of treatment-related adverse events (TRAEs).

The study is currently ongoing and will provide new insights into the benefits of combined radiotherapy and ­immunotherapy, in addition to efficient 68Ga-PSMA-11 PET/CT-base selection of patients with mCRPC.

Good tolerance to low dose 177Lu-PSMA-617 therapy

At this year’s EANM, Irene Marini presented preliminary results of IRST-185.03, an open-label, single-center, phase 2, prospective study (NCT03454750) evaluating the efficacy and toxicity of low-dose ­radiometabolic therapy with 177Lu-PSMA-617 in advanced mCRPC. The study enrollment started in April 2017 and closed in October 2022 [9]. The primary objective of the study was efficacy, as assessed by best biochemical response (BR) defined as a PSA reduction of at least 50 % versus baseline value. Secondary objectives encompassed safety, PFS and OS. Inclusion criteria comprised histologically confirmed progressive prostate cancer with me­tastases documented by 68Gallium-­PSMA-11 PET/CT scan, adequate hematological organ function and ECOG score ≤ 2.

In total, 43 patients were included in the low-dosage (LD) group (3.7-4.4 GBq per cycle) and 99 patients in the high-dosage (HD) group (5.5 GBq per cycle) based on age (cut-off at 75 years), prior treatment with docetaxel and risk factors for toxicity. The median age was 70.2 years and median PSA value was 45.7 ng/mL at baseline. Overall, 90.1 % of patients had received prior treatment with abiraterone/enzalutamide and 62.7 % with docetaxel, while 29.6 % had been rechallenged with cabazitaxel or docetaxel. To note, 37.2 % of patients presented more than 20 bone metastatic lesions and 17.6 % had visceral metastases. Both groups received a ­median of four cycles (up to six) of 177Lu-PSMA-617, eight to twelve weeks apart, with concomitant mannitol ­intra-venous infusion for kidney pro­tection and polyglutamate folate tablets orally for salivary glands pro­tection [10].

After a median follow-up of 28.8 months, the PSA ≥50 % was achieved in 40.1 % of all patients; in more detail, a PSA reduction of ≥50 % was observed in 42.4 % patients in the HD group and in 34.9 % of patients in the LD group ­(Figure 1). Moreover, 51.4 % of the overall patient population showed a PSA ­reduction < 30 % or a PSA increase. The overall median PFS was 7.0 months (95 % CI: 5.5-7.6) and the 12-month PFS rate was 18.9 % (95 % CI: 12.2-26.6). The overall median OS was 16.8 months (95 % CI: 12.1-20.4) – 13.5 months (95 % CI: 8.4-19.2) in the LD group and 16.4 months (95 % CI: 12.1-25.3) in the HD group. The overall 12-month OS rate was 60.4 % (95 % CI: 50.5-68.6) – 51.1 % (95 % CI: 35.5-64.8) in the LD group and 64.9 % (95 % CI: 51.9-75.1) in the HD group.

The most common side effect was grade 1 anemia reported in 19 patients. Grade 3 toxicity was observed in seven patients, with five experiencing anemia and two experiencing renal toxicity. No grade 4 toxicity was reported.

These preliminary results show that 177Lu-PSMA-617, even at low doses, is ­efficient and well tolerated in selected, heavily pretreated mCRPC patients and justify further investigation of the minimum effective and non-toxic dosage of this radiometabolic therapy.

Figure 1: PSA response after (A) low-dose (3.7-4.4 GBq) and (B) high-dose (5.5 GBq) 177Lu-PSMA-617 treatment in mCRPC.

Figure 1: PSA response after (A) low-dose (3.7-4.4 GBq) and (B) high-dose (5.5 GBq) 177Lu-PSMA-617 treatment in mCRPC.

Swiss registry of mCRPC patients treated with 177Lu-PSMA-I&T

The objective of this prospective national registry is to assess the efficacy and the safety of 177Lu-PSMA-I&T (for imaging and therapy) therapying mCRPC implemented in daily clinical practice in ­Switzerland. Between February 2021 and May 2023, eight sites enrolled 246 ­patients with mCRPC, defined by ­PSMA-positivity, who failed or were unfit for chemotherapy, and had a progressive disease despite androgen-­signaling inhibition therapy. During last year’s EANM, Nicolas Guillaume already presented preliminary safety (primary endpoint) and efficacy (key secondary endpoint) data from 107 patients receiving 7 GBq of 177Lu-PSMA-I&T every six weeks [11]. This year, Alin Chirindel presented an update on 147 evaluable patients [12]; a follow-up is planned ­until May 2024.

The enrolled patients had a median age of 75 years, a median baseline PSA of 72 ng/ml and metastases mostly in bones (95 % of patients) and/or lymph nodes (77 %). In the prior phase 3 ­VISION trial (NCT03511664), 50 % of patients had lymph node metastases and 21 % had metastases in soft tissues, compared to 30 % in the Swiss registry [13]. In total, 70 % of patients had a Gleason score between eight and ten, 71 % had received previous chemotherapy (97 % in VISION) and 99 % had underwent androgen-signaling inhibition therapy or orchidectomy (100 % in ­VISION). Patients received a median of three treatment cycles (IQR: 2-5) with a median of 7.1 GBq 177Lu-PSMA (IQR: 6.5-7.5), while VISION patients received a median of five cycles (IQR: 1-6).

A biochemical response was observed in 58.1 % of patients, with PSA levels ≤80 % in 18.2 % and ≤50 % in 39.9 % of patients. An objective imaging response – as evaluated by the tumor total volume [14] – was observed in 78 % of patients. The median PSA response and the ­median OS (15.2 months) are in line with the efficacy parameters observed with 177Lu-PSMA-617 in the VISION trial ­(Table 1 and [13]).

Treatment related grade ≥3 adverse events (AEs), shown in Table 1, include lymphopenia (27.8 %), anemia (13.6 %), leukopenia (3.4 %), kidney dysfunction (1.4 %) and thrombocytopenia (1.4 %).

The preliminary Swiss registry radioligand therapy data show that 177Lu-­PSMA-I&T has a good safety profile and is efficient in mCRPC patients in a ­real-life setting.

Table Preliminary safety and efficacy results from the Swiss registry and the VISION phase 3 trial

Combined therapy with 225Ac-PSMA-617 and 177Lu-PSMA

Treatment options in patients with mCRPC after failure of guideline-­conform or 177Lu-PSMA-radioligand therapies are very limited [15]. While 225Ac-PSMA-617-targeted alpha therapy (TAT) has demonstrated promising ­results in these patients, its associated adverse effects could substantially ­affect the quality of life of these patients [16]. A combination treatment regimen with 177Lu-PSMA and reduced 225Ac-TAT may improve tolerability, while maintaining an acceptable antitumor activity. At EANM 2023, Gabriel T. Sheikh presented the study outcomes in terms of response and adverse events in patients receiving different combinations of 225Ac-TAT/177Lu-PSMA-I&T (ALCT) [17].

A total of 22 mCRPC patients who failed previous guideline-based and/or 177Lu-PSMA-radioligand therapy were treated with ALCT: ten patients (Group 1) received 4 MBq 225Ac and 4000 MBq 177Lu, three patients (Group 2) received 6 MBq 225Ac and 1000 or 2000 MBq 177Lu, and nine patients (Group 3) received 8 MBq 225Ac and 1000 MBq 177Lu per therapy cycle. Clinical parameters (PSA, alkaline phosphatase, lactate ­dehydrogenase, hemoglobin, leukocyte count, thrombocyte count, creatinine) and imaging parameters from 18F-­PSMA-PET/CT (Tumor Total Volume, SUVmax, SUVmean) were collected at baseline and after two cycles of therapy. AEs were evaluated according to ­CTCAE v5.0 and 18F-PSMA-PET/CT according to RECIP 1.0 (response evaluation criteria in PSMA PET/CT, [18]).

Regarding the efficacy of the three ALCT combinations, as evaluated by ­either clinical or imaging parameters, there was no statistically significant ­difference between the groups. AEs in Group 1, 2 and 3 after two cycles of ALCT included anemia in 20 %, 0 % and 33 %; thrombocytopenia in 10 %, 0 % and 0 %; leukopenia in 40 %, 33 % and 22 %; weight loss in 10 %, 0 % and 22 %, as well as xerostomia in 30 %, 33 % and 56 %, ­respectively. Overall, a higher 177Lu-activity was associated with bone marrow toxicity, while higher 225Ac-activity was more ­frequently associated xerostomia.

The three tested combinations of 225Ac-TAT/177Lu-PSMA-I&T showed an overall similar efficacy but different ­tolerability. Therefore, ALCT with low 225Ac-activity could be a favorable choice to minimize adverse effects on salivary glands. Nevertheless, it is ­imperative to closely monitor these ­patients for any changes in hematology parameters.

REFERENCES

  1. Lowrance WT et al. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. J Urol. 2018; 200(6): 1264-1272
  2. Sekhoacha M et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022; 27(17): 5730
  3. Wang F et al. Advances in PSMA-targeted therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2022; 25(1): 11-26
  4. Langbein T et al. Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation. Diagnostics (Basel). 2022; 12(8): 1926
  5. Niaz MO et al. Review of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for the treatment of metastatic castration-resistant prostate cancer. Cureus. 2020; 12(2): e7107
  6. Sartor O et Baghian A. Prostate specific ­membrane antigen binding radiopharmaceuticals: ­Current data and new concepts. Front Med ­(Lausanne). 2022; 9:1060922
  7. Batra JS et al. Phase I trial of docetaxel plus ­lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. Urol Oncol. 2020; 38(11): 848.e9-848.e16
  8. Patel N et al. ProstACT GLOBAL: a phase 3 study of 177Lu-DOTA-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug. EANM 2023 (Oral abstract OP-718)
  9. Marini I et al. 177Lu-PSMA-617 therapy in ­advanced mCRPC patients: preliminary results of the phase 2 prospective trial IRST-185.03. EANM 2023 (Oral abstract OP-723)
  10. Paganelli G et al. Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020; 47(13): 3008-3017
  11. Nicolas G et al. Safety and efficacy of PSMA targeted radionuclide therapy with 177Lu-ITG-PSMA-1 in metastatic castration resistant prostate cancer patients: preliminary results of a Swiss wide prospective multicentre registry study. EANM 2022 (Oral abstract OP-381)
  12. Chirindel A et al. Safety and efficacy of PSMA-targeted radionuclide therapy with 177Lu-ITG-PSMA-1 in metastatic castration resistant prostate cancer patients: Update on the prospective, multicenter, Swiss registry study. EANM 2023 (Oral abstract OP-716)
  13. Sartor O et al. VISION investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021; 385(12): 1091-1103
  14. John N et al. 177Lu-PSMA SPECT Quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy. J Nucl Med. 2023; 64(3): 410-415
  15. Unterrainer LM et al. Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T. Bio­medicines. 2022; 10(5): 946
  16. Ma J et al. Efficacy and safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022; 12: 796657
  17. Sheikh G et al. Systematic evaluation of response and adverse events in mCRPC patients treated with different combinations of 225Ac/177Lu-PSMA-therapy. EANM 2023 (Oral abstract OP-717)
  18. Gafita A et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022; 63(11): 1651-1658

© 2023 Springer-Verlag GmbH, Impressum

More posts

ALK 阳性疾病：推动可治疗性突破界限

ALK 阳性、晚期 NSCLC 患者的标准治疗包括第一代 ALK 抑制剂克唑替尼，以及新近的第二代 ALK TKI，如色瑞替尼和艾乐替尼。全球 III 期 ALEX 试验在 IIIB/IV 期 ALK 阳性 NSCLC 患者中测试了作为一线药物的高选择性、CNS 活性 ALK 抑制剂艾乐替尼，并与克唑替尼相比较。本研究允许无症状脑转移。根据初步分析，艾乐替尼治疗改善了研究人员评估的 PFS（不可评估对比 11.1 个月；HR，0.47；p

访谈：“定序问题仍然存在

我认为这是一个非常有意思的治疗方案。我们知道阿法替尼对治疗肺鳞状细胞癌确实有效。LUX-Lung 8 试验表明 PFS 和 OS 相较厄洛替尼有所改善[1]。我们的加拿大试验证明，在二线环境中，厄洛替尼确实在鳞状细胞癌中具有疗效[2]。我们知道阿法替尼是一种非常有效的药物，我们也知道派姆单抗在肿瘤表达 PD-L1 的患者接受含铂双联疗法后对鳞状细胞癌有效。因此，我认为这两种药剂相结合将会非常有意思。正在进行的研究是一项 II 期试验，旨在研究肿瘤尺寸的缩减 [3]。该组合的耐受性应该很好，我也希望看到更高的反应率。

关于跨 3 个世代的 EGFR 靶向 TKI 的新数据

EGFR TKI 治疗已成为晚期、 EGFR 突变阳性 NSCLC 患者的标准一线治疗策略。药物包括第一代药物吉非替尼和厄洛替尼，第二代药物阿法替尼和达克替尼，以及第三代 TKI 奥希替尼。 EGFR TKI 与其他药物的组合可以优化预后，例如抗血管生成药物额外用药，如贝伐单抗和雷莫芦单抗。

免疫检查点阻滞：治疗成功的决定因素

PD-L1表达之外的各种临床因素，已作为对免疫检查点抑制产生反应的预测因子经过探索。具体而言，分析将缺少烟草暴露与 NSCLC 中 PD-1 通路阻滞的反应性降低相关联[1,2]。出现这种情况的一种可能解释是，从不吸烟或很少吸烟的肺癌患者通常显示低 TMB [3]。随着吸烟暴露的增加，每兆碱基的突变数量也会增加。TMB 已被确定为免疫检查点抑制剂反应的独立预测生物标志物，高 TMB 表示更有利的反应 [4,5]。

PD-(L)1 单独和联合抑制：近期对免疫疗法的见解

转移性非小细胞肺癌 (NSCLC) 患者与化疗相比，使用抗-PD-1 单克隆抗体派姆单抗的单药疗法显著改善了临床疗效指标。除了无进展生存期 (PFS) 获益外，KEYNOTE-024 显示总生存 (OS) 有所提高；此外，接受派姆单抗治疗的患者比接受化疗的患者具有更好的安全性。 由于对转移性 NSCLC 的更有效和可耐受的一线治疗方案未满足部分需求，KEYNOTE-042 研究了派姆单抗在表达 PD-L1 的任何组织学的先前未治疗、局部晚期或转移性肺肿瘤患者中的作用（肿瘤比例评分[TPS]≥1％），但未发现致敏 EGFR 或 ALK 改变。

前言

作为医师和研究人员，我们很幸运能够参与由精准医学带来的癌症研究和治疗的重大创新。虽然精准医学似乎是在一夜之间取得成功，但它实际上是一种经过深思熟虑的战略研究途径，基于来自世界各地的潜心研究的科学家数十年来艰苦、有素的工作。在肺癌中，精准医学帮助确定致癌基因，以便用靶向疗法进行有效治疗，而免疫疗法的兴起，也在过去 10 到 15 年内对许多患者的治疗发挥关键作用。